Interim treatment selection using the normal approximation approach in clinical trials.

Methods of designing two-stage winner trials with survival outcomes. Stat Med (2013) 0.75

Efficient Adaptive Randomization and Stopping Rules in Multi-arm Clinical Trials for Testing a New Treatment. Seq Anal (2015) 0.75

Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology (2012) 8.29

Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2012) 1.78

Design and sample size considerations for simultaneous global drug development program. J Biopharm Stat (2012) 1.39

Increasing the sample size when the unblinded interim result is promising. Stat Med (2004) 1.14

Applying the law of iterated logarithm to control type I error in cumulative meta-analysis of binary outcomes. Clin Trials (2007) 0.94

Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study. Clin Ther (2012) 0.91

Conditional bias of point estimates following a group sequential test. J Biopharm Stat (2004) 0.80

Monitoring mortality at interim analyses while testing a composite endpoint at the final analysis. Control Clin Trials (2003) 0.80

Proposals of statistical consideration to evaluation of results for a specific region in multi-regional trials--Asian perspective. Pharm Stat (2010) 0.77

Microperimetric assessment of retinal sensitivity in eyes with diabetic macular edema from a phase 2 study of intravitreal aflibercept. Retina (2015) 0.76

Effect of Fluid Status at Week 12 on Visual and Anatomic Outcomes at Week 52 in the VIEW 1 and 2 Trials. Ophthalmic Surg Lasers Imaging Retina (2016) 0.76

Spending functions and continuous-monitoring boundaries. Stat Med (2012) 0.75

The use of weighted Z-tests in medical research. J Biopharm Stat (2005) 0.75